Mediterr J Rheumatol 2023;34(3):367-71
Tofacitinib in Refractory Scleritis: A Case Series
Authors Information

1Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India

2Department of Ophthalmology, S.C.B Medical College, Cuttack, Odisha, India

S Dey, R Sarkar, A Pradhan, P Padhan, D Maikap


Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.

Cite this article as: Dey S, Sarkar R, Pradhan A, Padhan P, Maikap D. Tofacitinib in Refractory Scleritis: A Case Series. Mediterr J Rheumatol 2023;34(3):367-71


Article Submitted: 24 Mar 2023; Revised Form: 16 Jul 2023; Article Accepted: 19 Jul 2023; Available Online: 28 Aug 2023


This work is licensed under a Creative Commons Attribution 4.0 International License.